Irritable Bowel Syndrome and Motility Center

• Achalasia
• Gastroesophageal reflux disease (GERD)
• Functional dyspepsia
• Irritable bowel syndrome (IBS)
• Constipation
• Fecal incontinence
• Intestinal pseudo-obstruction

• Esophageal Manometry
• Esophagogram
• Endoflip
• 24-Hour pH Testing
• Impedance pH Testing
• Bravo pH Study
• Gastric Emptying Study
• SmartPill
• Breath Testing
• Sitzmarks
• Anorectal Manometry
• Defogram
• Anorectal Biofeedback

• Nutrition counseling
• Food allergy testing
• Cognitive behavior feedback
• Pelvic floor biofeedback
• Pain management
• IBS education and support
• Clinical trials for new IBS and chronic constipation therapies
• Complementary and alternative therapies such as hypnosis, acupuncture, relaxation response, and guided imagery

The IBS & Motility Center at Beth Israel Deaconess Medical Center is focused on advancing knowledge on the pathophysiology and treatment of functional gastrointestinal (FGID) and motility disorders. In addition to conducting research studies looking at the biological causes and psychosocial components of FGIDs and motility disorders, we are committed to investigating new potential treatments.

Besides participating in clinical trials for investigational new drugs, our Center is the leading center for complementary and alternative treatments for FGIDs. Some of our current enrolling clinical research studies include:

• AK002 for Eosinophilic Gastritis and/or Eosinophilic Duodenitis - This study is evaluating the efficacy of AK002 in treating symptoms of eosinophilic gastritis and/or duodenitis through the elimination of eosinophils. Eligible patients who complete this trial have the option to enter into the open label extension.
• AK002 for Eosinophilic Esophagitis (EoE) - Lirentelimab (AK002) is a humanized monoclonal antibody that was shown to eliminate eosinophils, the cells that are thought to cause the symptoms of EoE. This study seeks to evaluate if AK002 is an effective treatment for patient with active EoE symptoms that failed other standard therapies. Eligible patients that completed the trial have the option to enter into an open label extension.
• CIN-102 for Gastroparesis - CIN-102 is a modified form of domperidone that has been formulated to reduce the risk of cardiac side effects. This study is to assess the safety and efficacy of the CIN-102 in gastroparesis with 2 weeks of treatment.
• Crofelemer for Functional Diarrhea - Crofelemer is a natural supplement currently FDA-approved for noninfectious diarrhea in HIV patients. This study is investigating whether it is also effective for chronic diarrhea due to other causes.
• Effect of low FODMAP diet on SIBO - SIBO is a condition defined by excessive and/or abnormal type of bacteria in the small bowel which can lead to increased gas and bloating. The low FODMAP diet replaces foods known to increase gas production in the gut with foods that are less likely to produce gas. This study evaluates the effect of the low FODMAP diet on SIBO.
• Multi-strain synbiotic (probiotic and prebiotic combination) for IBS-C and IBS-M - DS-01 is a combination of a 24 different probiotic strains. This study is evaluating its impact on pre-menopausal women and men with IBS-C and IBS-M.
• TAK-906 for Gastroparesis - TAK-906 is an investigational drug that works similarly to reglan and domperidone. It has been formulated however to minimize the risk of extrapyramidal and cardiac side effects. This study is evaluating the efficacy of TAK-906 in improving gastroparesis symptoms with 12 weeks of treatment.
• Tradipitant for Gastroparesis - Tradipitant was previously shown to improve symptoms of nausea in patients with gastroparesis in its phase 2 study. This study is a phase 3 study that will further evaluate its efficacy in improving gastroparesis symptoms with 12 weeks of treatment.
• Vibrating capsule for chronic constipation - The Vibrant capsule is a non-drug mechanical capsule that vibrates in the colon causing the muscles to contract and push stool through the colon.

If you are interested in participating in one of these studies, or learning more information, please call 617-667-0682 or email us.